Ion Beam Applications SA (IBAB.BR)
- Previous Close
11.12 - Open
11.26 - Bid --
- Ask --
- Day's Range
11.16 - 11.48 - 52 Week Range
9.40 - 15.14 - Volume
43,269 - Avg. Volume
39,206 - Market Cap (intraday)
337.828M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
42.15 - EPS (TTM)
0.27 - Earnings Date May 22, 2025
- Forward Dividend & Yield 0.17 (1.53%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
17.50
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. It Also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
www.iba-worldwide.comRecent News: IBAB.BR
View MorePerformance Overview: IBAB.BR
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBAB.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBAB.BR
View MoreValuation Measures
Market Cap
326.61M
Enterprise Value
326.15M
Trailing P/E
41.09
Forward P/E
10.39
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.71
Price/Book (mrq)
3.62
Enterprise Value/Revenue
0.70
Enterprise Value/EBITDA
11.99
Financial Highlights
Profitability and Income Statement
Profit Margin
1.86%
Return on Assets (ttm)
2.89%
Return on Equity (ttm)
8.52%
Revenue (ttm)
498.16M
Net Income Avi to Common (ttm)
9.25M
Diluted EPS (ttm)
0.27
Balance Sheet and Cash Flow
Total Cash (mrq)
72.58M
Total Debt/Equity (mrq)
39.39%
Levered Free Cash Flow (ttm)
4.75k